Journal
PHARMACEUTICS
Volume 11, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics11110588
Keywords
antimicrobial peptide; anticancer peptide; nanoparticle; metal nanoparticle; nanotoxicity; liposome
Categories
Funding
- Fundacao para a Ciencia e a Tecnologia-Ministerio da Ciencia, Tecnologia e Ensino Superior (FCT-MCTES) through Fundos do Orcamento de Estado (Portugal) [UID/BIM/50005/2019]
Ask authors/readers for more resources
Antimicrobial peptides (AMPs) have been described as excellent candidates to overcome antibiotic resistance. Frequently, AMPs exhibit a wide therapeutic window, with low cytotoxicity and broad-spectrum antimicrobial activity against a variety of pathogens. In addition, some AMPs are also able to modulate the immune response, decreasing potential harmful effects such as sepsis. Despite these benefits, only a few formulations have successfully reached clinics. A common flaw in the druggability of AMPs is their poor pharmacokinetics, common to several peptide drugs, as they may be degraded by a myriad of proteases inside the organism. The combination of AMPs with carrier nanoparticles to improve delivery may enhance their half-life, decreasing the dosage and thus, reducing production costs and eventual toxicity. Here, we present the most recent advances in lipid and metal nanodevices for AMP delivery, with a special focus on metal nanoparticles and liposome formulations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available